Roland Gander

Novartis Opens Second Biotech Facility in Austria

The pharmaceutical company Novartis has commissioned its second state-of-the-art cell culture facility for the production of monoclonal antibodies in Kundl (Kufstein district). The opening of the facility, which has been invested in with a total of €500 million, along with its sister facility in Schaftenau (Kufstein district), which opened in June 2024, is seen as a strong signal for the Austrian life sciences sector. With this expansion, Novartis is creating around 100 new jobs in Kundl and strengthening its global production capacity.

14 hours ago

Swiss Novartis Opens Fastest Cell Culture Facility in Tyrol

Novartis opened a state-of-the-art cell culture facility for the production of monoclonal antibodies in Schaftenau, Tyrol.

June 24, 2024
Fast News Search